Trial Profile

Hispanic/Latino and Non-Hispanic BlAck Patients Treated with NiRaparib and Abiraterone Acetate Plus Prednisone for Metastatic HOrmone Sensitive Prostate Cancer with Deleterious Homologous RecombinatioN Repair Alterations: a Phase II, Open Label StudY

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abiraterone acetate (Primary) ; Abiraterone acetate/niraparib (Primary) ; Docetaxel (Primary) ; Prednisone (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms HARMONY

10 Jun 2025 Planned initiation date changed from 1 May 2025 to 1 Jul 2025.
04 May 2025 Planned initiation date (estimated date of first patient enrollment) changed from 1 Apr 2025 to 1 May 2025.
22 Apr 2025 Planned initiation date changed from 1 Mar 2025 to 1 Apr 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com